|
| Friday, 11 September 2020, 09:41 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Sept 11, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020. The abstracts highlight updates regarding Eisai's in-house discovered LENVIMA (lenvatinib mesylate, the orally available kinase inhibitor, "lenvatinib"), Halaven (eribulin mesylate, halichondrin class microtubule dynamics inhibitor, "eribulin") and its liposomal formulation.
There will be two oral presentations regarding the combination therapy of lenvatinib and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside of the United States and Canada)'s anti-PD-1 antibody, KEYTRUDA (pembrolizumab). Both of these presentations have been selected as Late-Breaking Abstracts. The interim results of the phase 2 study (LEAP-004) in advanced melanoma which had been treated with an anti-PD-1 or PD-L1 antibody (Abstract No: LBA44), as well as the interim results of the basket-type phase 2 study (LEAP-005) for 6 types (triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, glioblastoma, and biliary tract cancer) of previously treated, advanced solid tumors (Abstract No: LBA41) will be presented.
There will also be an e-poster presentation (Abstract No: 346P) on the expansion cohort of HER2-negative breast cancer in a phase 1 study evaluating the eribulin liposomal formulation (E7389-LF) which aims to realize the efficient delivery to tumors.
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
